Latest clinical findings from the first-in-human engineered macrophage trial Registration

Start Date:6/24/2022

Start Time:1:00 PM EDT

Duration:75 minutes

Background:

Join Carisma Therapeutics scientific leaders for a live webcast on the latest findings from the CT-0508 clinical trial: an immunotherapy leveraging CAR-macrophages in patients with HER2 overexpressing solid tumors.

Carisma Therapeutics is currently running the first clinical trial evaluating engineered macrophages for patients with hard-to-treat solid tumors. Learn more about the power of this novel immunotherapy and how to enroll. www.carismatx.com

If you're already registered for the latest clinical findings from the first-in-human engineered macrophage trial webcast, click below:

ALREADY REGISTERED?

Speakers

Michael Klichinsky, PhD, PharmD

Chief Scientific Officer

Carisma Therapeutics

Mike is co-inventor of the CAR-Macrophage technology and a scientific co-founder of Carisma Therapeutics Inc.

Ramona Swaby, MD

Vice President Clinical Development

Carisma Therapeutics

Dr. Ramona Swaby is a medical oncologist who was a prior clinical investigator specializing in breast cancer treatment and research prior to transitioning to fulltime drug development, and now serves as Vice President for Clinical Development at Carisma.

Steven Kelly

President & CEO

Carisma Therapeutics

Steven Kelly joined Carisma Therapeutics as Chief Executive Officer in February 2018 bringing nearly thirty years of experience in Pharma/Biotech at all phases of the business across multiple therapeutic categories.